natgillin/translations-raw huggingface dataset:
De reviderede årlige overvågningsprogrammer gælder udelukkende den pågældende medlemsstats indenlandske kvægpopulation og omfatter som minimum alt kvæg på over 48 måneder, som tilhører følgende delpopulationer:
The revised annual monitoring programmes shall apply only to the national bovine population of the concerned Member State and shall cover at least all bovine animals above 48 months of age belonging to the following subpopulations:
dyr omhandlet i kapitel A, del I, punkt 2.2, i bilag III til forordning (EF) nr. 999/2001
animals as referred to in point 2.2 of Part I of Chapter A of Annex III to Regulation (EC) No 999/2001;
dyr omhandlet i kapitel A, del I, punkt 2.1, i bilag III til forordning (EF) nr. 999/2001
animals as referred to in point 2.1 of Part I of Chapter A of Annex III to Regulation (EC) No 999/2001;
dyr omhandlet i kapitel A, del I, punkt 3.1, i bilag III til forordning (EF) nr. 999/2001.
animals as referred to in point 3.1 of Part I of Chapter A of Annex III to Regulation (EC) No 999/2001.
Denne beslutning er rettet til Kongeriget Belgien, Kongeriget Danmark, Forbundsrepublikken Tyskland, Irland, Den Hellenske Republik, Kongeriget Spanien, Den Franske Republik, Den Italienske Republik, Storhertugdømmet Luxembourg, Kongeriget Nederlandene, Republikken Østrig, Den Portugisiske Republik, Republikken Finland, Kongeriget Sverige og Det Forenede Kongerige Storbritannien og Nordirland.
This Decision is addressed to the Kingdom of Belgium, the Kingdom of Denmark, the Federal Republic of Germany, Ireland, the Hellenic Republic, the Kingdom of Spain, the French Republic, the Italian Republic, the Grand Duchy of Luxembourg, the Kingdom of Netherlands, the Republic of Austria, the Portuguese Republic, the Republic of Finland, the Kingdom of Sweden and the United Kingdom of Great Britain and Northern Ireland.
Liste over medlemsstater
List of Member States
om ændring af del 1 og del 2 i Schengenkonsultationsnettet (tekniske specifikationer)
amending Parts 1 and 2 of the Schengen consultation network (technical specifications)
under henvisning til Republikken Sloveniens initiativ, og
Having regard to the initiative by the Republic of Slovenia,
For at nå frem en pragmatisk tilgang og undgå overbelastning af Schengenkonsultationsnettet ved at sende et stort antal fejlmeldinger, når en medlemsstats message transfer agent (MTA) midlertidigt ikke synes at være tilgængelig, bør genfremsendelsesproceduren ændres.
In order to achieve a pragmatic approach and to avoid overburdening the Schengen consultation network by sending a high number of error messages when a Member State’s message transfer agent (MTA) seems to be temporarily unavailable, the resend procedure should be modified.
For at undgå inkonsekvent anvendelse af forskellige visumtypekoder, der kan føre til fejlfortolkninger i Schengen konsultationsprocedurerne i forbindelse med behandling af visumansøgninger, er der brug for en fælles tilgang, når visa af typen D + C indgår i en konsultationsprocedure.
In order to avoid inconsistent use of different visa type codes which could lead to misinterpretations in the Schengen consultation procedure, a common approach is needed when visas D + C are subject to the consultation procedure.
Under hensyn til input fra forskellige medlemsstater og for at forenkle Schengenkonsultationsproceduren bør der anvendes én enkelt kode for hver visumtype.
Taking into account the inputs from different Member States and in order to simplify the Schengen consultation procedure, a single code for each visa type should be used.
Det er nødvendigt at ajourføre de tekniske specifikationer for Schengenkonsultationsnettet for at sikre, at de afspejler disse ændringer.
It is necessary to update the technical specifications of the Schengen consultation network to ensure that they reflect these changes.
Inden seks måneder efter, at Rådet har truffet afgørelse om denne beslutning til udbygning af Schengenreglerne efter bestemmelserne i tredje del, afsnit IV, i traktaten om oprettelse af Det Europæiske Fællesskab, træffer Danmark afgørelse om, hvorvidt det vil gennemføre denne beslutning i sin nationale lovgivning, jf. artikel 5 i protokollen om Danmarks stilling.
Given that this Decision builds upon the Schengen acquis under the provisions of Title IV of Part Three of the Treaty establishing the European Community, Denmark is to decide, in accordance with Article 5 of the said Protocol, within a period of six months after the adoption of this Decision whether it will implement it in its national law.
For Islands og Norges vedkommende er denne beslutning et led i udviklingen af de bestemmelser i Schengenreglerne, jf. aftalen indgået mellem Rådet for Den Europæiske Union og Republikken Island og Kongeriget Norge om disse to staters associering i gennemførelsen, anvendelsen og udviklingen af Schengenreglerne [2], der falder ind under artikel 1, litra A, i Rådets afgørelse 1999/437/EF [3] om visse gennemførelsesbestemmelser til nævnte aftale.
As regards Iceland and Norway, this Decision constitutes a development of provisions of the Schengen acquis within the meaning of the Agreement concluded by the Council of the European Union and the Republic of Iceland and the Kingdom of Norway concerning the latters’ association with the implementation, application and development of the Schengen acquis [2], which fall within the area referred to in Article 1, point A of Council Decision 1999/437/EC [3] on certain arrangements for the application of that Agreement.
For Schweiz’ vedkommende er denne beslutning et led i udviklingen af de bestemmelser i Schengenreglerne, jf. aftalen mellem Den Europæiske Union, Det Europæiske Fællesskab og Det Schweiziske Forbund om Det Schweiziske Forbunds associering i gennemførelsen, anvendelsen og udviklingen af Schengenreglerne [4], der falder ind under det område, der er nævnt i artikel 1, litra A, i Rådets afgørelse 1999/437/EF sammenholdt med artikel 3 i Rådets afgørelse 2008/146/EF [5] om indgåelse, på Det Europæiske Fællesskabs vegne, af denne aftale.
As regards Switzerland, this Decision constitutes a development of provisions of the Schengen acquis within the meaning of the Agreement between the European Union, the European Community and the Swiss Confederation concerning the association of the Swiss Confederation with the implementation, application and development of the Schengen acquis [4], which fall within the area referred to in Article 1, point A of Decision 1999/437/EC read in conjunction with Article 3 of Council Decision 2008/146/EC [5] on the conclusion, on behalf of the European Community, of that Agreement.
Hvad angår Liechtenstein udgør denne forordning en udbygning af bestemmelserne i Schengenreglerne som omhandlet i protokollen mellem Den Europæiske Union, Det Europæiske Fællesskab, Det Schweiziske Forbund og Fyrstendømmet Liechtenstein om Fyrstendømmet Liechtensteins tiltrædelse af aftalen mellem Den Europæiske Union, Det Europæiske Fællesskab og Det Schweiziske Forbund om Det Schweiziske Forbunds associering i gennemførelsen, anvendelsen og udviklingen af Schengenreglerne, som falder ind under det område, der er omhandlet i artikel 1, litra A, i Rådets afgørelse 1999/437/EF sammenholdt med artikel 3 i Rådets afgørelse 2008/261/EF [6] om undertegnelse, på Det Europæiske Fællesskabs vegne, af og midlertidig anvendelse af visse bestemmelser i nævnte protokol.
As regards Liechtenstein, this Decision constitutes a development of provisions of the Schengen acquis within the meaning of the Protocol between the European Union, the European Community, the Swiss Confederation and the Principality of Liechtenstein on the accession of the Principality of Liechtenstein to the Agreement between the European Union, the European Community and the Swiss Confederation on the Swiss Confederation’s association with the implementation, application and development of the Schengen acquis, which fall within the area referred to in Article 1, point A of Decision 1999/437/EC read in conjunction with Article 3 of Council Decision 2008/261/EC [6] on the signature, on behalf of the European Community, and on the provisional application of certain provisions of that Protocol.
Denne beslutning er et led i udviklingen af de bestemmelser i Schengenreglerne, som Det Forenede Kongerige ikke deltager i, jf. Rådets afgørelse 2000/365/EF af 29. maj 2000 om anmodningen fra Det Forenede Kongerige Storbritannien og Nordirland om at deltage i visse bestemmelser i Schengenreglerne [7]; Det Forenede Kongerige deltager derfor ikke i vedtagelsen af denne forordning, som ikke er bindende for og ikke finder anvendelse i Det Forenede Kongerige.
This Decision constitutes a development of provisions of the Schengen acquis in which the United Kingdom does not take part, in accordance with Council Decision 2000/365/EC of 29 May 2000 concerning the request of the United Kingdom of Great Britain and Northern Ireland to take part in some of the provisions of the Schengen acquis [7]; the United Kingdom is therefore not taking part in its adoption and is not bound by it or subject to its application.
Denne beslutning er et led i udviklingen af de bestemmelser i Schengenreglerne, som Irland ikke deltager i, jf. Rådets afgørelse 2002/192/EF af 28. februar 2002 om anmodningen fra Irland om at deltage i visse bestemmelser i Schengenreglerne [8]; Irland deltager derfor ikke i vedtagelsen af denne forordning, som ikke er bindende for og ikke finder anvendelse i Irland.
This Decision constitutes a development of provisions of the Schengen acquis in which Ireland does not take part, in accordance with Council Decision 2002/192/EC of 28 February 2002 concerning Ireland’s request to take part in some of the provisions of the Schengen acquis [8]; Ireland is therefore not taking part in its adoption and is not bound by it or subject to its application.
Hvad angår Cypern, udgør denne beslutning en retsakt, der bygger på Schengenreglerne eller på anden måde har tilknytning dertil, jf. artikel 3, stk. 2, i tiltrædelsesakten fra 2003
As regards Cyprus, this Decision constitutes an act building on the Schengen acquis or otherwise related to it within the meaning of Article 3(2) of the 2003 Act of Accession.
Denne beslutning udgør en retsakt, der bygger på Schengenreglerne eller på anden måde har tilknytning dertil, jf. artikel 4, stk. 2, i tiltrædelsesakten fra 2005 —
This Decision constitutes an act building on the Schengen acquis or otherwise related to it within the meaning of Article 4(2) of the 2005 Act of Accession,
Del 1 i Schengenkonsultationsnettet (tekniske specifikationer) ændres som anført i bilag I.
Part 1 of the Schengen consultation network (technical specifications) is amended as shown in Annex I.
Del 2 i Schengenkonsultationsnettet (tekniske specifikationer) ændres som anført i bilag II.
Part 2 of the Schengen consultation network (technical specifications) is amended as shown in Annex II.
Denne beslutning anvendes fra 1. februar 2009.
This Decision shall apply from 1 February 2009.
I del 1 i Schengenkonsultationsnettet (tekniske specifikationer) foretages følgende ændringer:
Part 1 of the Schengen consultation network (technical specifications) is hereby amended as follows:
They must resend messages which have not been delivered, but not overload other partner systems by, for example, unnecessary repetition of messages which are thought to have been lost.«
They must resend messages which have not been delivered, but not overload other partner systems by, for example, unnecessary repetition of messages which are thought to have been lost.’;
Punkt 1.2.1 affattes således:
point 1.2.1 shall be replaced by the following:
In case of regular maintenance, such as database backups, the maintenance slot shall not exceed a maximum of two hours.
In case of regular maintenance, such as database backups, the maintenance slot shall not exceed a maximum of two hours,
store the equivalent of two days operations, i.e. a maximum of 100 Megabytes
store the equivalent of two days operations, i.e. a maximum of 100 Megabytes,
send up to 30000 messages and 30000 delivery reports per day
send up to 30000 messages and 30000 delivery reports per day,
In addition, each Schengen State must distinguish between »retransmitting« and »resending as a new message«.
In addition, each Schengen State must distinguish between “retransmitting” and “resending as a new message”.
The term »re-send« in the next chapters (especially 1.2.2) covers both cases, but the following distinction must be made:
The term “re-send” in the next chapters (especially 1.2.2) covers both cases, but the following distinction must be made:
»retransmitting« means sending again the same message, usually subject to retransmission parameters of the MTA (e.g. sendmail, MS-Exchange, Lotus Notes).
“retransmitting” means sending again the same message, usually subject to retransmission parameters of the MTA (e.g. sendmail, MS-Exchange, Lotus Notes).
»resending as a new message« means that a new message with the same content is prepared.
“resending as a new message” means that a new message with the same content is prepared.
Schengen States are invited to use the first possibility (retransmitting) wherever possible, to avoid the unnecessary multiplying of messages in the system.«
Schengen States are invited to use the first possibility (retransmitting) wherever possible, to avoid the unnecessary multiplying of messages in the system.’
I del 2 i Schengenkonsultationsnettet (tekniske specifikationer) foretages følgende ændringer:
Part 2 of the Schengen consultation network (technical specifications) is hereby amended as follows:
I punkt 2.1.4 affattes Heading No 026 således:
in point 2.1.4, Heading No 026 shall be replaced by the following:
»Heading No 026: Type of visa format: code (2)
‘Heading No 026: Type of visa format: code (2)
long-stay visas valid concurrently as short-stay visas«
long-stay visas valid concurrently as short-stay visas’;
I punkt 2.1.4 (Form A), 2.1.6 (Form C), 2.1.7 (Form F), affattes indholdet af række 026 i femte kolonne i tabellen (»Examples/Comments«) således:
in points 2.1.4 (Form A), 2.1.6 (Form C), 2.1.7 (Form F), the content of row 026 in the fifth column of the table (‘Examples/Comments’) shall be replaced by the following:
»C ′B
‘C B
′DC′«.
′DC′’.
After each retransmission there are no more messages in the system, the first message is just transmitted again.
After each retransmission there are no more messages in the system, the first message is just transmitted again;
om udarbejdelse af en liste over droger, drogetilberedninger og sammensætninger heraf til brug i traditionelle plantelægemidler
establishing of a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products
(meddelt under nummer K(2008) 6933)
(notified under document number C(2008) 6933)
under henvisning til Europa-Parlamentets og Rådets direktiv 2001/83/EF af 6. november 2001 om oprettelse af en fællesskabskodeks for humanmedicinske lægemidler [1], særlig artikel 16f,
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [1], and in particular Article 16(f) thereof,
under henvisning til udtalelse fra Det Europæiske Lægemiddelagentur, udarbejdet af Udvalget for Plantelægemidler den 7. september 2007, og
Having regard to the opinions of the European Medicines Agency, formulated on 7 September 2007 by the Committee for Herbal Medicinal Products,
Foeniculum vulgare Miller subsp. vulgare var. vulgare og Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung opfylder kravene i direktiv 2001/83/EF.
Foeniculum vulgare Miller subsp. vulgare var. vulgare and Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung comply with the requirements set out in Directive 2001/83/EC.
Foeniculum vulgare Miller subsp. vulgare var. vulgare og Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung kan betragtes som droger, drogetilberedninger og/eller sammensætninger heraf.
Foeniculum vulgare Miller subsp. vulgare var. vulgare and Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung can be considered as herbal substances, herbal preparations and/or combinations thereof.
Det er derfor hensigtmæssigt at udarbejde en liste over droger, drogetilberedninger og sammensætninger heraf til brug i traditionelle plantelægemidler og at opføre Foeniculum vulgare Miller subsp. vulgare var. vulgare og Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung på listen.
It is therefore appropriate to establish a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products including the entry of Foeniculum vulgare Miller subsp. vulgare var. vulgare and the entry of Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung.
Foranstaltningerne i denne beslutning er i overensstemmelse med udtalelse fra Det Stående Udvalg for Humanmedicinske Lægemidler —
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,
Der udarbejdes en liste over droger, drogetilberedninger og sammensætninger heraf til brug i traditionelle plantelægemidler i bilag I, og Foeniculum vulgare Miller subsp. vulgare var. vulgare og Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung opføres på listen.
A list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products is established in Annex I including the entry of Foeniculum vulgare Miller subsp. vulgare var. vulgare and the entry of Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung.
Indikationer, nærmere angiven styrke og dosering, administrationsvej og eventuelle andre nødvendige oplysninger for sikker anvendelse som et traditionelt lægemiddel af relevans for Foeniculum vulgare Miller subsp. vulgare var. vulgare og Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung findes i bilag II til denne beslutning.
The indications, the specified strengths and the posology, the route of administration and any other information necessary for the safe use as a traditional medicinal product relevant for Foeniculum vulgare Miller subsp. vulgare var. vulgare and Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung are set out in Annex II to this decision.
Liste over droger, drogetilberedninger og sammensætninger heraf til brug i traditionelle plantelægemidler udarbejdet i overensstemmelse med artikel 16f i direktiv 2001/83/EF som ændret ved direktiv 2004/24/EF
List of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established in accordance with Article 16f of Directive 2001/83/EC as amended by Directive 2004/24/EC
Foeniculum vulgare Miller subsp. vulgare var. vulgare (Fennikel, bitter)
Foeniculum vulgare Miller subsp. vulgare var. vulgare (bitter fennel fruit)
Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (Fennikel, sød)
Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (sweet fennel fruit)
OPFØRELSE PÅ FÆLLESSKABSLISTEN AF FOENICULUM VULGARE MILLER SUBSP.
COMMUNITY LIST ENTRY ON FOENICULUM VULGARE MILLER SUBSP.
Plantens videnskabelige navn
Scientific name of the plant
Botanisk familie
Botanical family
Droge
Herbal substance
Drogens fællesnavn på alle officielle EU-sprog
Common name in all EU official languages of herbal substance
Drogetilberedning(er)
Herbal preparation(s)
Fennikel, bitter, tørret findelt [1] frugtHenvisning til Den Europæiske Farmakopés monografi
Fennel, bitter, dried comminuted [1] fruit.European Pharmacopoeia monograph reference
Traditionelt plantelægemiddel til behandling af symptomer på lettere fordøjelsesbesvær som mavekneb, oppustethed og tarmluft.
Traditional herbal medicinal product for symptomatic treatment of mild, spasmodic gastro-intestinal complaints including bloating and flatulence.
Traditionelt plantelægemiddel til symptomatisk behandling af let krampe ved menstruation.
Traditional herbal medicinal product for symptomatic treatment of minor spasm associated with menstrual periods.
Traditionelt plantelægemiddel, der anvendes som slimløsende middel ved hoste under forkølelse.
Traditional herbal medicinal product used as an expectorant in cough associated with cold.
Produktet er et traditionelt plantelægemiddel, som anvendes til de angivne indikationer. Indikationerne bygger alene på lang tids anvendelse.
The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.
Traditionens art
Type of tradition
Europæisk, kinesisk
European, Chinese.
Nærmere angiven styrke
Specified strength
Der henvises til »Nærmere angiven dosering«
Please see ‘Specified posology’.
Nærmere angiven dosering
Specified posology
1,5 til 2,5 g (frisk [2]) findelt fennikelfrugt med 0,25 l kogende vand (trækker i 15 minutter) tre gange dagligt som urtete.
1,5 to 2,5 g of (freshly [2]) comminuted fennel fruits with 0,25 l of boiling water (brew for 15 minutes) three times daily as a herbal tea.
Unge over 12 år, Indikation a)
Adolescents over 12 years of age, indication (a)
Samme dosering som til voksne
Adult dose
Børn mellem 4 og 12 år, Indikation a)
Children between four and 12 years of age, indication (a)
Gennemsnitlig dagsdosis
Average daily dose
3-5 g (frisk) findelt frugt som urtete, fordelt på tre doser, kun til kortvarig anvendelse ved lette, forbigående symptomer (af mindre end en uges varighed).
3-5 g of (freshly) comminuted fruits as a herbal tea, in three divided doses, for short-term use in mild transitory symptoms only (less than one week).
Bør ikke anvendes til børn under 4 år (se punktet »Særlige advarsler og forsigtighedsregler vedrørende brugen«).
The use in children under four years of age is not recommended (see section ‘Special warnings and precautions for use’).
Anvendelsens varighed eller eventuelle begrænsninger for anvendelsens varighed
Duration of use or any restrictions on the duration of use
Må højst anvendes i 2 uger.
Not to be taken for more than two weeks.
Kun til korttidsbrug (i under en uge) ved lette, forbigående symptomer.
For short-term use in mild transitory symptoms only (less than one week).
Søg lægehjælp, hvis symptomerne ikke forsvinder ved brugen af plantelægemidlet.
If the symptoms persist during the use of the medicinal product, a doctor or a qualified health-care practitioner should be consulted.
Eventuelle andre nødvendige oplysninger for sikker anvendelse
Any other information necessary for the safe use
Overfølsomhed over for den aktive substans eller over for Apiaceae (Umbelliferae) (anisfrø, kommen, selleri, koriander og dild) eller over for anetol.
Hypersensitivity to the active substance or to Apiaceae (Umbelliferae) (aniseed, caraway, celery, coriander and dill) or to anethole.
Bør ikke anvendes til børn under 4 år, da de foreliggende oplysninger ikke er tilstrækkelige. Søg rådgivning hos en børnelæge.
The use in children under four years of age is not recommended due to the lack of adequate data and a paediatrician’s advice should be sought.
Er ikke beskrevet.
None reported.
Der foreligger ingen oplysninger om anvendelse af fennikel til gravide.
There are no data from the use of fennel fruit in pregnant patients.
Det vides ikke, om bestanddelene i fennikel udskilles i modermælk.
It is unknown if fennel constituents are excreted in human breast milk.
Da der ikke foreligger tilstrækkelige oplysninger, bør plantelægemidlet ikke anvendes under graviditet og amning.
In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Der er ikke udført undersøgelser af virkningen på evnen til at føre motorkøretøj eller betjene maskiner.
No studies on the effect on the ability to drive and use machines have been performed.
Der kan forekomme allergiske reaktioner over for fennikel, med påvirkning af hud og åndedrætssystem.
Allergic reactions to fennel, affecting the skin or the respiratory system may occur.
Søg lægehjælp, hvis du får andre bivirkninger end de nævnte.
If other adverse reactions not mentioned above occur, a doctor or a qualified health-care practitioner should be consulted.